Streetbeat News

Stock Prices

GLTO

Galecto, Inc. (NASDAQ:GLTO) presented encouraging clinical data from its Phase 1b/2a GALLANT-1 trial at the ESMO Congress 2023. The trial studies the combination of atezolizumab and GB1211 in treating non-small cell lung cancer. The company reported a 60% response rate in patients who received GB1211 for at least three weeks, compared to a 22-38% response rate with atezolizumab monotherapy. Galecto has decided not to initiate Part B of the GALLANT-1 trial and will instead focus on severe liver diseases. The company will continue to supply GB1211 for an upcoming Phase 2 trial.

Portfolio Pulse from Happy Mohamed

October 23, 2023 | 12:14 pm

ESMT

Shares of EngageSmart have resumed trading.

Portfolio Pulse from Benzinga Newsdesk

October 23, 2023 | 12:12 pm

DM

JELD

LLAP

WNS

The article lists four industrial stocks that are considered oversold and may present a buying opportunity. These include Desktop Metal, Inc. (DM), WNS (Holdings) Limited (WNS), Terran Orbital Corporation (LLAP), and JELD-WEN Holding, Inc. (JELD). The companies have reported various updates including termination of shareholder rights plan, revenue reports, public offerings, and quarterly results.

Portfolio Pulse from Lisa Levin

October 23, 2023 | 12:11 pm

AMAM

Ambrx Biopharma, Inc. (NASDAQ:AMAM) has announced promising results from the Phase 1 portion of the ongoing APEX-01 trial for ARX517, a PSMA-targeted ADC. The trial demonstrated a 52% PSA50 reduction and a highly differentiated safety and PK profile in patients with mCRPC, who had progressed on multiple FDA-approved treatments. The data also showed a strong and highly differentiated safety profile across 65 patients at all dose levels with no treatment-related SAEs or DLTs.

Portfolio Pulse from Happy Mohamed

October 23, 2023 | 12:10 pm

TSLA

Tesla, Inc. (NASDAQ:TSLA) shares are trading lower in premarket trading on Monday, extending the lean patch seen since last Wednesday. The company's Q3 results showed both top-and bottom-line misses amid further margin erosion. CEO Elon Musk did not offer any clarity on the margin trajectory and expressed caution regarding the production ramp-up of the upcoming Cybertruck. Despite price cuts, the company has not seen the intended effect of lifting volume. The stock could also be reacting to the rising bond yields, which make equities less attractive.

Portfolio Pulse from Shanthi Rexaline

October 23, 2023 | 12:06 pm

ESMT

EngageSmart has agreed to be acquired by Vista Equity Partners for $4.0 billion. The shares of EngageSmart will be purchased for $23.00 per share in cash.

Portfolio Pulse from Benzinga Newsdesk

October 23, 2023 | 12:01 pm

CRM

36 analysts have provided ratings for Salesforce (NYSE:CRM) over the last quarter, with the majority being bullish or somewhat bullish. The average price target has increased by 6.8% from the previous average, implying an upside from the current price of $200.0.

Portfolio Pulse from Benzinga Insights

October 23, 2023 | 12:01 pm

CMG

In the last quarter, Chipotle Mexican Grill (NYSE:CMG) received mostly bullish and somewhat bullish ratings from analysts. The average 12-month price target for the company is $2180.91, a 1.26% decrease from the previous average of $2208.81.

Portfolio Pulse from Benzinga Insights

October 23, 2023 | 12:00 pm

CELH

Celsius Holdings (NASDAQ:CELH) has received positive analyst ratings in the last quarter, with 5 bullish and 4 somewhat bullish ratings. Over the past 3 months, 9 analysts have offered 12-month price targets for Celsius Holdings, with an average price target of $202.89, a high of $250.00, and a low of $155.00. The average price target has increased by 18.19% over the past month.

Portfolio Pulse from Benzinga Insights

October 23, 2023 | 12:00 pm

FMC

FMC Corporation has revised its Q4 revenue outlook downwards from $1.66 billion-$1.78 billion to $1.139 billion-$1.379 billion, against an estimated $1.67 billion.

Portfolio Pulse from Benzinga Newsdesk

October 23, 2023 | 12:00 pm